-
Photovoltaic 24
-
Wind energy 6
-
Other renewable energy (nuclear, geothermal, etc.) 22
-
Grid/power transmission 23
-
Energy storage 31
-
Hydrogen energy 10
-
Lithium batteries 48
-
Electric vehicles 45
-
Low-carbon buildings and construction 7
-
Agriculture 11
-
Low-carbon consumer goods 6
-
New materials 22
-
Industrial manufacturing 7
-
Green transportation 22
-
CCUS 2
-
Digital technology for carbon accounting and consulting 22
-
Bio-Tech 2
-
Circular economy 31
All investors
114 institutional investors
Content Filter
-
Photovoltaic 24
-
Wind energy 6
-
Other renewable energy (nuclear, geothermal, etc.) 22
-
Grid/power transmission 23
-
Energy storage 31
-
Hydrogen energy 10
-
Lithium batteries 48
-
Electric vehicles 45
-
Low-carbon buildings and construction 7
-
Agriculture 11
-
Low-carbon consumer goods 6
-
New materials 22
-
Industrial manufacturing 7
-
Green transportation 22
-
CCUS 2
-
Digital technology for carbon accounting and consulting 22
-
Bio-Tech 2
-
Circular economy 31
-
CAS Investment
- Investments: 152
- Funds: 15
- Beijing
-
Grid/power transmission
-
New materials
CAS Investment Management Co., Ltd. (abbreviated as CASI)' s controlling shareholder is Chinese Academy of Sciences Holdings Co., Ltd. and has State-owned Assets Supervision and Administration Commission of the State Council and an employee-owned company as shareholders. Its predecessor is the Chinese National Economic Council-CAS Scientific and Technological Promotion & Economic Development Foundation. In 1993, it set up China Scientific and Technological Promotion Investment Company in line with Chinese policies governing foundations. In 2006, it was restructured into a limited liability company and changed to its present name. The key industries invested by CASI include instrumentation and high-end equipment manufacturing, information technology, pharmaceutical chemical industry and new materials, modern service industry, etc., and the company have successively supported more than 300 industrialization projects of scientific and technological achievements. CASI is committed to becoming a leading private equity fund manager in China.
-
Panlin Capital
- Investments: 88
- Funds: 21
- Shanghai
-
Lithium batteries
-
Agriculture
-
Circular economy
Panlin Capital is a technologically innovative early and mid-term venture capital institution focusing on biotechnology and data intelligence applications under the theme of "Technology Innovation Leads Consumption Upgrade". Panlin Capital has been focusing on independent innovation opportunities in the medical and technological fields and promoting the development of China's private economy in the long run. We look for entrepreneurs among scientists and innovators among entrepreneurs, cultivate Chinese scientific and technological innovation enterprises with capital investment, and promote the transformation of China's economic structure and the rapid development of new economy with the power of science and technology. The companies invested by Panlin Capital mainly include Bio Kangtai, Apollomics, Genfleet, Carrier Gene, Ruiyun Cold Chain, Passion Tech, etc.
-
Security Capital
- Investments: 37
- Funds: 2
- Beijing
-
Grid/power transmission
Security Capital, founded in September 2017, is an investment institution focusing on network information security initiated and established by Qi 'an Xin, the largest network security enterprise in China, together with Guoxing Capital, Kingray Capital, and the management team. Our core team members are from China's domestic network information security companies and professional investment institutions such as DTT, CETC, CCID, and Qi'an Xin. We have many years of experience in communication, Internet, network and information security industry background and investment to ensure our specialized, marketized, and standardized project investment and fund management skills. Through cultivated investment research, industrial investment and ecological investment management, we create the network security industry ecology for the invested enterprises, network security leading enterprises, Party A customers, industry summit, industrial alliance and third-party service institutions to achieve common growth.
-
SBCVC
- Investments: 345
- Funds: 59
- Suzhou, Jiangsu Province
-
Agriculture
-
New materials
-
Other renewable energy (nuclear, geothermal, etc.)
SoftBank China Venture Capital (SBCVC), established in 2000, is a venture capital and private equity fund management company dedicated to investing in outstanding high-growth and high-tech enterprises in Greater China. It has successfully invested in Alibaba, Taobao, Focus Media, Global Data Solutions, BGI, Dean Diagnostics, Edan and a series of outstanding enterprises. At present, SBCVC manages several USD and RMB funds at the same time, and its investment fields include information technology, medical and health care, clean technology, consumer retail and high-end manufacturing industries. SBCVC's team is committed to investing in outstanding high-growth and high-tech enterprises in Greater China by using its successful entrepreneurial experience and rich investment experience.
-
YINGKE PE
- Investments: 188
- Funds: 116
- Fuzhou, Fujian Province
-
Lithium batteries
-
New materials
Yingke PE is a mixed-ownership asset management company with 30% equity held by state-owned capital. With the mission of "discovering the power of economic development", Yingke PE ranks among the top 6 Chinese venture capital institutions, with an asset management scale of nearly 50 billion yuan. 90% of the entrusted funds come from large institutions including financial institutions and state-owned enterprises. We focus on biological medicine and hard technology, search for technologically innovative enterprises that conform to the national development strategy and possess key technology. We adhere to the double strategy of "biological medicine industry investment + life sciences industry holding" and have invested in nearly 300 high quality projects. Nearly 60% of our investment is in the biological medicine industry. IWe are known as the entry level investment institution platform for capital to enter the biomedical circuit.